In the treatment for glioblastoma (GBM), treatment modalities, such as bevacizumab (BEV) and carmustine wafers implants have been approved in Japan since 2013. However, it is unclear whether such a trend in treatment complexity can accelerate treatment centralization. The aim of this study was to...
As TAMs depend on colony-stimulating factor (CSF) for differentiation and survival, BLZ945, a CSF-1 inhibitor, has been used to target TAMs in mouse glioblastoma models. The results showed that the inhibition of CSF-1 could decrease the M2 macrophage frequency in the TAM populations, leading ...
Simple Summary: Glioblastoma (GBM) poses a formidable challenge as a central nervous system tumor with extremely limited responsiveness to conventional treatments. While immunotherapeutic approaches have shown success in treating other solid tumors, their effectiveness against GBM is limited....
Glioblastoma (GBM) is the most common high-grade primary malignant brain tumor with an extremely poor prognosis. Given the poor survival with currently approved treatments for GBM, new therapeutic strategies are urgently needed. Advances in decades of investment in basic science of glioblastoma are ra...
Glioblastoma multiforme (GBM) is the most common primary malignant brain tumor, and it is associated with poor prognosis. Its characteristics of being highly invasive and undergoing heterogeneous genetic mutation, as well as the presence of the blood–br
[17,157]. The problem of drug resistance also hinders the efficacy of treatment for glioblastoma patients. Consequently, an efficacious therapy for glioblastoma must be established [167]. An in vitro investigation demonstrated that GA in both human glioma U251n and U87 cells inhibited glioma cell ...
[90,91]. Notably, CRISPRoff was used to suppress the expression of Tau, a microtubule-associated protein linked to Alzheimer’s disease, in vitro, supporting its further exploration for treatments of neurodegenerative diseases [90]. In future and ongoing work, CRISPRoff-mediated silencing activity...
In conclusion, the era of precision oncology holds promise for targeting EGFR in glioblastoma, contingent on tailored treatments, effective blood鈥揵rain barrier navigation, and the exploration of synergistic therapies.International Journal of Molecular SciencesEzzati, ShawyonSalib, SamuelBal...
Novel locoregional treatments, as well as strategies to improve regional delivery, are being evaluated. Studies of combinations of these approaches are also underway. In this review, we will discuss the current and future therapies under evaluation for the treatment of malignant gliomas....
However, there have been far more failures than successes in developing immunotherapeutic treatments for SCLC. Even the most promising combination strategy of first-line chemotherapy plus anti-PD-L1 or PD-1 only achieved limited efficacy for ES-SCLC, with a median survival increase of approximately ...